View Future GrowthDT Cloud Star Acquisition 過去の業績過去 基準チェック /26DT Cloud Star Acquisition は平均年間 80.8% の収益成長を遂げていますが、Capital Markets 業界では年間 収益成長率 となっています。5.8% です。主要情報80.81%収益成長率70.34%EPS成長率Capital Markets 業界の成長10.26%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updates新しいナラティブ • Jun 18A SPAC in the Endgame Between Lifeboat and Siren SongThe Metaphor Upfront: Investing in DTSQ is like buying a ticket on a lifeboat whose captain has just decided to purchase a luxuriously labeled but barely inspected cargo ship in the middle of the open sea. Those who disembark in time get their money back plus a small interest premium.お知らせ • Apr 12DT Cloud Star Acquisition Corp Receives Notice of Non-Compliance with Nasdaq Listing Rule 5450(a)(2)On April 6, 2026, DT Cloud Star Acquisition Corporation (the Company) received a letter (the Deficiency Letter) from the Listing Qualifications Staff of The Nasdaq Stock Market (Nasdaq) indicating that based on a shareholder range analysis provided by the Company to Nasdaq dated March 27, 2026, the Company is not in compliance with Listing Rule 5450(a)(2) (the Minimum Public Holders Rule), which requires the Company to maintain at least 400 total holders for continued listing on The Nasdaq Global Market. The Deficiency Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Deficiency Letter states that the Company has 45 calendar days, or until May 21, 2026, to submit a plan to regain compliance with Listing Rule 5450(a)(2). If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance with Listing Rule 5450(a)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the Capital Market). The Company is exploring all options to regain compliance with Listing Rule 5450(a)(2) and intends to submit a plan to regain compliance within the required timeframe. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.お知らせ • Feb 05Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction.Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction on February 2, 2026. A cash consideration of $1.5 billion will be paid by Primegen Us, Inc. As part of consideration, $1.5 billion is paid towards common equity of DT Cloud Star Acquisition Corporation. The combined company is expected to operate as PrimeGen US. PrimeGen US is anticipated to list on the Nasdaq, subject to Nasdaq approval, under a new ticker symbol. The transaction is subject to subject to antitrust regulations, minimum balance sheet requirements, approval by regulatory board, approval of offer by acquirer shareholders and approval of offer by target shareholders. The transaction is currently expected to close in the second half of 2026. A.G.P. / Alliance Global Partners, LLC acted as financial advisor for Primegen Us, Inc. Sichenzia Ross Ference Carmel LLP acted as legal advisor for Primegen Us, Inc. Loeb & Loeb LLP acted as legal advisor for DT Cloud Star Acquisition Corporation. Steven C. Schinko of Schinko Law acted as legal advisor for Primegen Us, Inc.お知らせ • Jan 23DT Cloud Star Acquisition Corporation Receives A Deficiency Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn January 15, 2026, DT Cloud Star Acquisition Corporation received a letter (the “Deficiency Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on its Market Value of Listed Securities (“MVLS”) for the period from November 21, 2025 to January 6, 2026, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(b)(2)(A), to maintain a minimum MVLS of $50,0000,000. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until July 14, 2026, in which to regain compliance with Nasdaq continued listing requirement. Nasdaq will provide written confirmation of compliance to the Company and close this matter if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days during this compliance period. In the event the Company does not regain compliance prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting, in which situation the Company may appeal the delisting determination to a Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the “Capital Market”). The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(b)(2)(A), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.お知らせ • Nov 29DT Cloud Star Acquisition Corporation Appoints Xunyong Zhou as DirectorOn November 26, 2025, the board of directors of DT Cloud Star Acquisition Corporation (the “Company”) appointed Dr. Xunyong Zhou as a director of the Company. Dr. Zhou, aged 50, is an entrepreneur and researcher with over 6 years of experience in biotechnology and health innovation. Dr. Zhou’s main topic of research is enzyme-based theory for food products, cosmetics, daily chemicals and tea, and he holds over 20 patents as of now. Dr. Zhou is a pioneering figure in biotechnology and digital health innovation. He has served as director for Huakang Biomedical Holdings Company Limited since November 2025. Since January 2023, He has been leading advancements in biological enzyme solutions and cell therapy technologies through Nanjing Hezhen Holding Group Co. Ltd., where he serves as chairman and integrates healthcare generative pre-training transformer and enzyme therapy expertise to co-create a collaborative platform offering next-generation health solutions. Dr. Zhou also oversees Changsha Kerong Health Technology Co. Ltd., which has built a multidisciplinary health service team comprising medical, product, and service experts centered on delivering AI-enhanced health education, health consultation, and health management services. From March 2019 to January 2023, Dr. Zhou took the role of chairman for Zhenzhen Suqian Biotechnology Co. Ltd. Dr. Zhou graduated from Tianjin University of the PRC with a bachelor degree of engineering majoring in business administration in 2002 and Fudan University of the PRC with a master degree of laws in 2011. Dr. Zhou subsequently obtained his doctorate degree in business administration from the Université Nice Sophia Antipolis in Nice, France in 2016. He is currently the honorary chairman of the Vaccine and Immune Health Branch of the Liaoning Immunology Society and a member of the National Enzyme Engineering and Fermentation Engineering Professional Committee.お知らせ • Sep 12DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025, at 10:00 China Standard Time. Location: offices of loeb & loeb llp, 2206-19, 1 connaught pl, central, Hong Kongお知らせ • Apr 16Dt Cloud Star Acquisition Corporation Announces Chief Executive Officer Changes, Effective April 14, 2025DT Cloud Star Acquisition Corporation announced that effective April 14, 2025, Bian Fan was removed as Chief Executive Officer of DT Cloud Star Acquisition Corporation by the written consent of the board of directors of the Company. On the same date, to fill the vacancy, the Board appointed Sam Zheng Sun as the Chief Executive Officer of the Company. Mr. Sun was a managing director of the private equity investment department of Affinity Equity Partners, a Hong Kong-headquartered firm that focuses on private equity investments across South Korea, Australia and New Zealand, Greater China and Southeast Asia between March 2021 and February 2023. Prior to that, Mr. Sun was a partner at Sequoia Capital based in Beijing, where he focused on private equity investments, between October 2018 and April 2020. Mr. Sun obtained his MBA degree from UCLA Anderson School of Management in 2007 and Bachelor’s degree in computer science and economics from University of Pittsburgh in 1997.収支内訳DT Cloud Star Acquisition の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGM:DTSQ 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26011031 Dec 25021030 Sep 25030030 Jun 25030031 Mar 25020031 Dec 24010030 Sep 24000030 Jun 24000031 Mar 24000031 Dec 230000質の高い収益: DTSQは 高品質の収益 を持っています。利益率の向上: DTSQの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: DTSQの収益は過去 5 年間で年間80.8%増加しました。成長の加速: DTSQは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。収益対業界: DTSQは過去 1 年間で収益成長率がマイナス ( -24.1% ) となったため、 Capital Markets業界平均 ( 38.3% ) と比較することが困難です。株主資本利益率高いROE: DTSQの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YDiversified-financials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/13 05:08終値2026/07/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DT Cloud Star Acquisition Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
新しいナラティブ • Jun 18A SPAC in the Endgame Between Lifeboat and Siren SongThe Metaphor Upfront: Investing in DTSQ is like buying a ticket on a lifeboat whose captain has just decided to purchase a luxuriously labeled but barely inspected cargo ship in the middle of the open sea. Those who disembark in time get their money back plus a small interest premium.
お知らせ • Apr 12DT Cloud Star Acquisition Corp Receives Notice of Non-Compliance with Nasdaq Listing Rule 5450(a)(2)On April 6, 2026, DT Cloud Star Acquisition Corporation (the Company) received a letter (the Deficiency Letter) from the Listing Qualifications Staff of The Nasdaq Stock Market (Nasdaq) indicating that based on a shareholder range analysis provided by the Company to Nasdaq dated March 27, 2026, the Company is not in compliance with Listing Rule 5450(a)(2) (the Minimum Public Holders Rule), which requires the Company to maintain at least 400 total holders for continued listing on The Nasdaq Global Market. The Deficiency Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company's securities on the Nasdaq Global Market. The Deficiency Letter states that the Company has 45 calendar days, or until May 21, 2026, to submit a plan to regain compliance with Listing Rule 5450(a)(2). If Nasdaq accepts the Company's plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Deficiency Letter to evidence compliance with Listing Rule 5450(a)(2). If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal the decision to a Nasdaq Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the Capital Market). The Company is exploring all options to regain compliance with Listing Rule 5450(a)(2) and intends to submit a plan to regain compliance within the required timeframe. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirements.
お知らせ • Feb 05Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction.Primegen Us, Inc. agreed to acquire DT Cloud Star Acquisition Corporation (NasdaqGM:DTSQ) in a reverse merger transaction on February 2, 2026. A cash consideration of $1.5 billion will be paid by Primegen Us, Inc. As part of consideration, $1.5 billion is paid towards common equity of DT Cloud Star Acquisition Corporation. The combined company is expected to operate as PrimeGen US. PrimeGen US is anticipated to list on the Nasdaq, subject to Nasdaq approval, under a new ticker symbol. The transaction is subject to subject to antitrust regulations, minimum balance sheet requirements, approval by regulatory board, approval of offer by acquirer shareholders and approval of offer by target shareholders. The transaction is currently expected to close in the second half of 2026. A.G.P. / Alliance Global Partners, LLC acted as financial advisor for Primegen Us, Inc. Sichenzia Ross Ference Carmel LLP acted as legal advisor for Primegen Us, Inc. Loeb & Loeb LLP acted as legal advisor for DT Cloud Star Acquisition Corporation. Steven C. Schinko of Schinko Law acted as legal advisor for Primegen Us, Inc.
お知らせ • Jan 23DT Cloud Star Acquisition Corporation Receives A Deficiency Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn January 15, 2026, DT Cloud Star Acquisition Corporation received a letter (the “Deficiency Letter”) from the Listing Qualifications Staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that based on its Market Value of Listed Securities (“MVLS”) for the period from November 21, 2025 to January 6, 2026, the Company no longer meets the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(b)(2)(A), to maintain a minimum MVLS of $50,0000,000. Nasdaq has provided the Company with a compliance period of 180 calendar days, or until July 14, 2026, in which to regain compliance with Nasdaq continued listing requirement. Nasdaq will provide written confirmation of compliance to the Company and close this matter if the Company’s MVLS closes at $50,000,000 or more for a minimum of ten consecutive business days during this compliance period. In the event the Company does not regain compliance prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting, in which situation the Company may appeal the delisting determination to a Hearings Panel. The Company may also consider applying for a transfer to The Nasdaq Capital Market (the “Capital Market”). The Company is currently evaluating options to regain compliance and intends to timely regain compliance with Nasdaq’s continued listing requirement. Although the Company will use all reasonable efforts to achieve compliance with Rule 5450(b)(2)(A), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq continued listing requirement.
お知らせ • Nov 29DT Cloud Star Acquisition Corporation Appoints Xunyong Zhou as DirectorOn November 26, 2025, the board of directors of DT Cloud Star Acquisition Corporation (the “Company”) appointed Dr. Xunyong Zhou as a director of the Company. Dr. Zhou, aged 50, is an entrepreneur and researcher with over 6 years of experience in biotechnology and health innovation. Dr. Zhou’s main topic of research is enzyme-based theory for food products, cosmetics, daily chemicals and tea, and he holds over 20 patents as of now. Dr. Zhou is a pioneering figure in biotechnology and digital health innovation. He has served as director for Huakang Biomedical Holdings Company Limited since November 2025. Since January 2023, He has been leading advancements in biological enzyme solutions and cell therapy technologies through Nanjing Hezhen Holding Group Co. Ltd., where he serves as chairman and integrates healthcare generative pre-training transformer and enzyme therapy expertise to co-create a collaborative platform offering next-generation health solutions. Dr. Zhou also oversees Changsha Kerong Health Technology Co. Ltd., which has built a multidisciplinary health service team comprising medical, product, and service experts centered on delivering AI-enhanced health education, health consultation, and health management services. From March 2019 to January 2023, Dr. Zhou took the role of chairman for Zhenzhen Suqian Biotechnology Co. Ltd. Dr. Zhou graduated from Tianjin University of the PRC with a bachelor degree of engineering majoring in business administration in 2002 and Fudan University of the PRC with a master degree of laws in 2011. Dr. Zhou subsequently obtained his doctorate degree in business administration from the Université Nice Sophia Antipolis in Nice, France in 2016. He is currently the honorary chairman of the Vaccine and Immune Health Branch of the Liaoning Immunology Society and a member of the National Enzyme Engineering and Fermentation Engineering Professional Committee.
お知らせ • Sep 12DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025DT Cloud Star Acquisition Corporation, Annual General Meeting, Oct 08, 2025, at 10:00 China Standard Time. Location: offices of loeb & loeb llp, 2206-19, 1 connaught pl, central, Hong Kong
お知らせ • Apr 16Dt Cloud Star Acquisition Corporation Announces Chief Executive Officer Changes, Effective April 14, 2025DT Cloud Star Acquisition Corporation announced that effective April 14, 2025, Bian Fan was removed as Chief Executive Officer of DT Cloud Star Acquisition Corporation by the written consent of the board of directors of the Company. On the same date, to fill the vacancy, the Board appointed Sam Zheng Sun as the Chief Executive Officer of the Company. Mr. Sun was a managing director of the private equity investment department of Affinity Equity Partners, a Hong Kong-headquartered firm that focuses on private equity investments across South Korea, Australia and New Zealand, Greater China and Southeast Asia between March 2021 and February 2023. Prior to that, Mr. Sun was a partner at Sequoia Capital based in Beijing, where he focused on private equity investments, between October 2018 and April 2020. Mr. Sun obtained his MBA degree from UCLA Anderson School of Management in 2007 and Bachelor’s degree in computer science and economics from University of Pittsburgh in 1997.
